Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
9.2.2021 14:00:00 CET | Business Wire | Press Release
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005141/en/
The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics®. By cutting through silos and integrating a range of capabilities, outsourced development programs can be further simplified and accelerated, consistent with Quotient’s belief that molecules need to become cures, fast.
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018. Mark Bryant, BGF, said, “It has been a privilege to support the expansion of Arcinova’s world-leading CDMO facility at such a critical part of its growth journey. We wish the team all the best as it moves to the next stage with Quotient Sciences.”
RBC Capital Markets acted as exclusive financial advisor to Quotient Sciences. PwC provided financial and tax due diligence services and Latham & Watkins provided legal counsel. BGF received legal counsel from Weightmans. KPMG served as corporate finance adviser for Arcinova, and Womble Bond Dickinson provided legal counsel.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
About Arcinova
Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. The company, with decades of experience, combines agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products. Arcinova’s ambition is to save our clients valuable time, enabling them to rapidly bring life-changing medicines to market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005141/en/
Contact information
Jane Byram
SCORR Marketing
+1-512-626-2758
jane@scorrmarketing.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
South African Agency Boundless Delivers Mazda’s First AI-produced Commercial Using Luma Agents15.4.2026 21:07:00 CEST | Press Release
Luma AI today announced that Boundless, an independent creative agency based in Johannesburg, South Africa, has produced Mazda’s first AI-produced commercial using Luma Agents, Luma’s AI-powered creative workflow system. Delivered in less than two weeks from initial brief to final approval, the project marks a significant step in the use of AI-native workflows for commercial production. As part of the collaboration, Boundless has also signed an agreement with Luma to integrate the company’s AI technologies into its creative workflow across future client work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415098939/en/ The project marks a milestone for both Boundless and the broader advertising industry, demonstrating how AI-native workflows can help agencies compress production timelines while maintaining creative quality, brand consistency, and operational oversight. The campaign supports the re-entry of the Mazda MX-5
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom